Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Free Research Report on Jazz Pharmaceuticals, Inc., Furiex Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc., Prestige Brands Holdings, Inc. and Synta Pharmaceuticals, Inc.

JAZZ, PBH, VIRX
Free Research Report on Jazz Pharmaceuticals, Inc., Furiex Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc., Prestige Brands Holdings, Inc. and Synta Pharmaceuticals, Inc.

NEW YORK, January 30, 2013 /PRNewswire/ --

Today, Traders Insight announced new research reports highlighting Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ), Furiex Pharmaceuticals, Inc. (Nasdaq: FURX), Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), Prestige Brands Holdings, Inc. (NYSE: PBH) and Synta Pharmaceuticals, Inc. (Nasdaq: SNTA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Jazz Pharmaceuticals, Inc. Research Report
The Full Research Report on Jazz Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.TradersInsight.net/r/2013-01-29/4e94_JAZZ]

Furiex Pharmaceuticals, Inc. Research Report
Furiex Pharmaceuticals, Inc. is a drug development collaboration company. The Company's product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas. Its programs include Priligy, Alogliptin Nesina, Alogliptin/Actose Combination, Alogliptin/Metformin Combination, Fluoroquinolone, Mu Delta and PPD 10558. Priligy (dapoxetine) is a drug developed for the on-demand treatment of premature ejaculation (PE). The Full Research Report on Furiex Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.TradersInsight.net/r/2013-01-29/64fa_FURX]

Sunesis Pharmaceuticals, Inc. Research Report
Sunesis Pharmaceuticals, Inc. (Sunesis) is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The Company is focuses primarily on the development of vosaroxin for the treatment of acute myeloid leukemia (AML). Vosaroxin is a anti-cancer quinolone derivative (AQD). The Full Research Report on Sunesis Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.TradersInsight.net/r/2013-01-29/669a_SNSS]

Prestige Brands Holdings, Inc. Research Report
Prestige Brands Holdings, Inc. (Prestige) is a holding company. The Company, along with its subsidiaries, is engaged in the marketing, sales and distribution of over-the-counter (OTC) Healthcare and Household Cleaning brands to mass merchandisers, drug stores, supermarkets, club and dollar stores primarily in the United States and Canada. The Company conducts its operations through two principal business segments: Over-the-Counter Healthcare and Household Cleaning. The Full Research Report on Prestige Brands Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.TradersInsight.net/r/2013-01-29/7623_PBH]

Synta Pharmaceuticals, Inc. Research Report
Synta Pharmaceuticals Corp. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing small molecule drugs to severe the medical conditions of the patients with cancer and inflammatory diseases. As of December 31, 2011, it had two drug candidates in clinical trials for treating multiple types of cancer and several drug candidates in the preclinical-stage of development. The Full Research Report on Synta Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.TradersInsight.net/r/2013-01-29/8e0e_SNTA]


About Traders Insight
Our model of enabling open collaboration between members is breaking new ground into the investment community. By tapping into the resources of the community, we are crowd-sourcing our reach. As a result -- we have been able to identify some of the greatest moving companies on the market today. The evidence is in the results, join today and experience what you've been missing.


Press Contact:

Cora S. Patton
press@TradersInsight.net 
+1-203-297-6092 (North America)


SOURCE Traders Insight



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today